CV4 CUMULATIVE EXPOSURE TO CYCLOOXYGENASE-2 INHIBITORSAND CARDIOVASCULAR RISK
نویسندگان
چکیده
منابع مشابه
Cyclooxygenase inhibition and cardiovascular risk.
Over the past several months clinicians have been confronted at an escalating rate with reports describing the risks of COX-2 inhibitors (coxibs). Information on this class of drugs appears not only in traditional medical journals and textbooks, but also on the Web sites of regulatory agencies, professional societies, and pharmaceutical manufacturers.1–9 An unusual, but noteworthy, aspect of th...
متن کاملRisk of Cardiovascular Events and Cyclooxygenase-2 Inhibitors
Risk of cardiovascular events and cyclooxygenase-2 inhibitors Selective cyclooxygenase-2 (Cox-2) inhibitors have been at the centre of public attention since the revelation that the use of these drugs is associated with an increased risk of cardiovascular events (Tabrizchi 2005). Certainly pharmaco vigilance has an important place in the public domain and any new therapeutic information that le...
متن کاملCumulative Exposure to High‐Sensitivity C‐Reactive Protein Predicts the Risk of Cardiovascular Disease
BACKGROUND One measurement of hs-CRP (high-sensitivity C-reactive protein) is associated with increased risk of cardiovascular disease (CVD). The objective of this study was to characterize the association of cumulative exposure to increased hs-CRP with incident cardiovascular events. METHODS AND RESULTS We included 53 065 participants with hs-CRP measured at 3 examinations in 2006, 2008, and...
متن کاملCyclooxygenase-2 in Cardiovascular Biology
Cyclooxygenase (COX), also known as prostaglandin endoperoxide synthase, is the key enzyme required for the conversion of arachidonic acid to prostaglandins. Two COX isoforms have been identifi ed, COX-1 and COX-2. Generally, the COX-1 enzyme is produced constitutively (e.g. in gastric mucosa), whereas COX-2 is highly inducible (e.g. at sites of infl ammation and cancer). Traditional non-steroi...
متن کاملPrecaution, cyclooxygenase inhibition, and cardiovascular risk.
Cardiovascular risk led to the withdrawal of Vioxx (rofecoxib) in 2004. Some related drugs also increase cardiovascular risk and cyclooxygenase (COX)-2 inhibitors that remain on the market, including unselective non-steroidal anti-inflammatory drugs (NSAIDs), have not been exonerated. This article reviews if new evidence should change clinical and regulatory practice. Substantial COX-2 inhibiti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2005
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)62604-6